VolitionRx Limited to Present at 9th Annual Biotech Showcase Conference
Dec 01, 20168:57 AM
VolitionRx Limited to Attend Citi 2016 Global Healthcare Conference
Nov 11, 20166:30 AM
VolitionRx Limited to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2016
Nov 10, 20166:30 AM
VolitionRx Limited Announces Third Quarter 2016 Financial Results and Business Update
Nov 04, 20166:30 AM
VolitionRx Limited Schedules Third Quarter 2016 Earnings Conference Call and Business Update
Nov 03, 20166:30 AM
VolitionRx Limited and Hvidovre Hospital Begin Large Prospective Clinical Study
Oct 26, 20167:30 AM
VolitionRx Limited Announces Acquisition of New Belgian Facility and Appointment of COO to Belgian Volition
Oct 21, 201612:34 PM
VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriter
Oct 17, 20167:30 AM
Triage Blood Test Data Presented to Leading International Experts at the World Endoscopy Organization's Colorectal Cancer Screening Committee
Oct 11, 20169:30 AM
Data Presented at ESMO 2016 Demonstrates that VolitionRx Limited's Novel Blood Test for Colorectal Cancer Potentially Reduces the Need for Colonoscopy Referral by 25%
Oct 05, 20161:14 PM
VolitionRx Limited Announces Closing of Public Offering of Common Stock
Sep 30, 20169:45 AM
VolitionRx Limited Announces Pricing of Public Offering of Common Stock
Sep 29, 20165:02 PM
VolitionRx Limited Announces Proposed Public Offering of Common Stock
Sep 07, 20167:30 AM
VolitionRx to Attend Several Conferences in September
Sep 06, 20167:30 AM
Volition's Nu.Q Triage Colorectal Cancer Screening Test Expected to Reduce Colonoscopy Referral by 25 Percent
Sep 01, 20167:30 AM
VolitionRx Schedules Product Launch Update Conference Call for Tuesday, September 6, 2016 at 8:30 am ET
Aug 11, 20167:30 AM
VolitionRx Announces Second Quarter 2016 Financial Results and Business Update
Aug 08, 20167:30 AM
VolitionRx Schedules Second Quarter 2016 Earnings Conference Call and Business Update for Thursday, August 11, 2016 at 8:30am ET
Aug 02, 20168:00 AM
VolitionRx Engages Edison Advisors as Investor Relations Counsel
Jul 27, 20168:00 AM
VolitionRx Granted Fourth U.S. Patent
Jun 24, 20168:00 AM
VolitionRx Appoints Dr. Edward Futcher to Board of Directors
Jun 14, 20168:02 AM
VolitionRx Publishes Study Confirming Stability of Circulating Cell-Free Nucleosomes as Biomarkers for Cancer Diagnostic Blood Tests
May 31, 201610:16 AM
VolitionRx to Present at Two Upcoming Conferences in June
May 19, 20168:00 AM
VolitionRx to Present Data Demonstrating Accuracy of NuQ® Blood Test in Detecting Colorectal Cancer at World Endoscopy Organization (WEO) Meeting
May 13, 20168:00 AM
VolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 12, 20168:00 AM
VolitionRx Initiates Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ(R) Blood Test for Pancreatic Cancer
May 09, 20168:00 AM
VolitionRx Schedules First Quarter 2016 Earnings Conference Call and Business Update for Friday, May 13, 2016 at 8:30am ET
Apr 20, 201610:00 AM
VolitionRx Announces Study Results Showing NuQ® Blood Test Detects Prostate Cancer Early with Significantly Higher Accuracy than PSA Test
Apr 14, 20168:00 AM
VolitionRx Appoints Louise Day as Chief Marketing and Communications Officer
Apr 11, 20168:00 AM
VolitionRx to Participate in 2016 Morgan Stanley Healthcare Insight Series
Apr 08, 20168:00 AM
VolitionRx to Present at AACR Annual Meeting and Announce First Results from Prostate Cancer Study
Apr 07, 20168:08 AM
VolitionRx Announces CE Marks for Two NuQ® Blood Assays for Detection of Colorectal Cancer
Mar 23, 201611:30 AM
VolitionRx Announces Closing of Public Offering of Common Stock and Exercise of Over-Allotment Option in Full
Mar 18, 20169:29 AM
VolitionRx Announces Pricing of Public Offering of Common Stock
Mar 17, 20164:01 PM
VolitionRx Announces Proposed Public Offering of Common Stock
Mar 11, 20167:35 AM
VolitionRx Announces Full Year 2015 Financial Results and Business Update
Mar 09, 20168:30 AM
VolitionRx Schedules Full-Year 2015 Earnings Conference Call and Business Update for Friday, March 11, 2016 at 8:30am ET
Mar 09, 20167:00 AM
Preliminary Data Demonstrates 86% Accuracy in Detecting Idiopathic Pulmonary Fibrosis, a Fatal Lung Disease
Feb 17, 20167:00 AM
VolitionRx Demonstrates 75% Accuracy in Detecting Highest-Risk Pre-Cancerous Colorectal Adenomas with NuQ® Blood Test
Feb 04, 20167:00 AM
VolitionRx and Cancer Survivor Sean Swarner Celebrate World Cancer Day with Message of Hope for Cancer Survival Through Early Detection
Feb 04, 20167:00 AM
/C O R R E C T I O N -- VolitionRx Ltd/
Feb 02, 20167:00 AM
VolitionRx Initiates Prostate Cancer Study in Collaboration with the Surrey Cancer Research Institute, University of Surrey, UK
Jan 28, 20167:00 AM
VolitionRx Receives International ISO Certification for Quality Management System of its NuQ(R) Blood Tests
Jan 13, 20167:00 AM
VolitionRx Releases Annual Shareholder Update Letter
Jan 05, 20167:00 AM
VolitionRx Announces Dr. Jason Terrell's Transition to Full-Time Status as Chief Medical Officer and Head of U.S. Operations